Portfolio Companies

 RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing’s Syndrome ~ D...
Read more

An 18-month analysis shows that median Overall Survival (mOS) will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14....
Read more

HealthCap and Medicxi co-lead, joined by Forbion and Gimv Financing to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumours Dublin, I...
Read more

November 19, 2020 Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189....
Read more

Oslo, Norway, 19 November 2020 Nordic Nanovector ASA (OSE: NANO) announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-...
Read more

Oslo, Norway, 19 November 2020 Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's m...
Read more

PARIS, France and NEW YORK, N.Y.—November 18, 2020— Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inher...
Read more

–Successful Initiation of Late-Stage CAHmelia Program in Adult Classic CAH– –FDA and EMA Scientific Advice Support Plans in Pediatric Classic CAH Program– –IPO Results ...
Read more

Gothenburg, November 16, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announce...
Read more

Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhyth...
Read more